Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Arthritis, Rheumatoid 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Unresectable Pancreatic Carcinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Multi-centric Castleman's Disease 1Melanoma 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Colitis 1Castleman Disease 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Gemcitabine 35Cisplatin 21Capecitabine 17Oxaliplatin 16Leucovorin 11Fluorouracil 11pembrolizumab 8S 1 (combination) 8Nivolumab 6tremelimumab 5durvalumab 5Bevacizumab 5lenvatinib 4Irinotecan 4trametinib 3titanium silicide 3atezolizumab 3Radiofrequency Ablation 3zanidatamab 2vandetanib 2irinotecan sucrosofate 2derazantinib 2camrelizumab 2binimetinib 2apatinib 2Trastuzumab 2Tegafur 2Radiotherapy 2Panitumumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Biliary Tract Neoplasms × tocilizumab × Clear all
NCT04338685 2024-12-09

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Hoffmann-La Roche

Phase 1 Completed
55 enrolled 30 charts
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡